Anti-V3 Monoclonal Antibodies Display Broad Neutralizing Activities against Multiple HIV-1 Subtypes

被引:104
作者
Hioe, Catarina E. [1 ,2 ]
Wrin, Terri [3 ]
Seaman, Michael S. [4 ]
Yu, Xuesong [5 ]
Wood, Blake [5 ]
Self, Steve [5 ]
Williams, Constance [1 ]
Gorny, Miroslaw K. [1 ]
Zolla-Pazner, Susan [1 ,2 ]
机构
[1] NYU, Dept Pathol, Langone Sch Med, New York, NY 10016 USA
[2] Vet Affairs New York Harbor Healthcare Syst, New York, NY USA
[3] Monogram Biosci Inc, San Francisco, CA USA
[4] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Viral Pathogenesis, Boston, MA 02215 USA
[5] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Stat Ctr HIV AIDS Res & Prevent, Seattle, WA 98104 USA
来源
PLOS ONE | 2010年 / 5卷 / 04期
基金
美国国家卫生研究院;
关键词
HUMAN-IMMUNODEFICIENCY-VIRUS; V3; DOMAIN; TYPE-1; INFECTION; CLADE-B; CORECEPTOR SELECTIVITY; ENVELOPE GLYCOPROTEIN; CROSS-REACTIVITY; STRUCTURAL BASIS; BINDING MODE; ENV CLONES;
D O I
10.1371/journal.pone.0010254
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: The V3 loop of the HIV-1 envelope (Env) glycoprotein gp120 was identified as the "principal neutralizing domain'' of HIV-1, but has been considered too variable to serve as a neutralizing antibody (Ab) target. Structural and immunochemical data suggest, however, that V3 contains conserved elements which explain its role in binding to virus co-receptors despite its sequence variability. Despite this evidence of V3 conservation, the ability of anti-V3 Abs to neutralize a significant proportion of HIV-1 isolates from different subtypes (clades) has remained controversial. Methods: HIV-1 neutralization experiments were conducted in two independent laboratories to test human anti-V3 monoclonal Abs (mAbs) against pseudoviruses (psVs) expressing Envs of diverse HIV-1 subtypes from subjects with acute and chronic infections. Neutralization was defined by 50% inhibitory concentrations (IC(50)), and was statistically assessed based on the area under the neutralization titration curves (AUC). Results: Using AUC analyses, statistically significant neutralization was observed by >= 1 anti-V3 mAbs against 56/98 (57%) psVs expressing Envs of diverse subtypes, including subtypes A, AG, B, C and D. Even when the 10 Tier 1 psVs tested were excluded from the analysis, significant neutralization was detected by >= 1 anti-V3 mAbs against 46/88 (52%) psVs from diverse HIV-1 subtypes. Furthermore, 9/24 (37.5%) Tier 2 viruses from the clade B and C standard reference panels were neutralized by >= 1 anti-V3 mAbs. Each anti-V3 mAb tested was able to neutralize 28-42% of the psVs tested. By IC(50) criteria, 40/98 (41%) psVs were neutralized by >= 1 anti-V3 mAbs. Conclusions: Using standard and new statistical methods of data analysis, 6/7 anti-V3 human mAbs displayed cross-clade neutralizing activity and revealed that a significant proportion of viruses can be neutralized by anti-V3 Abs. The new statistical method for analysis of neutralization data provides many advantages to previously used analyses.
引用
收藏
页数:14
相关论文
共 63 条
[1]  
ALMOND D, AIDS RES HU IN PRESS
[2]   Structure of antibody f425-b4e8 in complex with a v3 peptide reveals a new binding mode for HIV-1 neutralization [J].
Bell, Christian H. ;
Pantophlet, Ralph ;
Schiefner, Andre ;
Cavacini, Lisa A. ;
Stanfield, Robyn L. ;
Burton, Dennis R. ;
Wilson, Ian A. .
JOURNAL OF MOLECULAR BIOLOGY, 2008, 375 (04) :969-978
[3]   Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies [J].
Binley, JA ;
Wrin, T ;
Korber, B ;
Zwick, MB ;
Wang, M ;
Chappey, C ;
Stiegler, G ;
Kunert, R ;
Zolla-Pazner, S ;
Katinger, H ;
Petropoulos, CJ ;
Burton, DR .
JOURNAL OF VIROLOGY, 2004, 78 (23) :13232-13252
[4]   Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection [J].
Bunnik, Evelien M. ;
Pisas, Linaida ;
van Nuenen, Ad C. ;
Schuitemaker, Hanneke .
JOURNAL OF VIROLOGY, 2008, 82 (16) :7932-7941
[5]   Structural Basis of the Cross-Reactivity of Genetically Related Human Anti-HIV-1 mAbs: Implications for Design of V3-Based Immunogens [J].
Burke, Valicia ;
Williams, Constance ;
Sukumaran, Madhav ;
Kim, Seung-Sup ;
Li, Huiguang ;
Wang, Xiao-Hong ;
Gorny, Miroslaw K. ;
Zolla-Pazner, Susan ;
Kong, Xiang-Peng .
STRUCTURE, 2009, 17 (11) :1538-1546
[6]   EFFICIENT NEUTRALIZATION OF PRIMARY ISOLATES OF HIV-1 BY A RECOMBINANT HUMAN MONOCLONAL-ANTIBODY [J].
BURTON, DR ;
PYATI, J ;
KODURI, R ;
SHARP, SJ ;
THORNTON, GB ;
PARREN, PWHI ;
SAWYER, LSW ;
HENDRY, RM ;
DUNLOP, N ;
NARA, PL ;
LAMACCHIA, M ;
GARRATTY, E ;
STIEHM, ER ;
BRYSON, YJ ;
CAO, YZ ;
MOORE, JP ;
HO, DD ;
BARBAS, CF .
SCIENCE, 1994, 266 (5187) :1024-1027
[7]   Structural basis for coreceptor selectivity by the HIV type 1 V3 loop [J].
Cardozo, Timothy ;
Kimura, Tetsuya ;
Philpott, Sean ;
Weiser, Barbara ;
Burger, Harold ;
Zolla-Pazner, Susan .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2007, 23 (03) :415-426
[8]   Worldwide Distribution of HIV Type 1 Epitopes Recognized by Human Anti-V3 Monoclonal Antibodies [J].
Cardozo, Timothy ;
Swetnam, James ;
Pinter, Abraham ;
Krachmarov, Chavdar ;
Nadas, Arthur ;
Almond, David ;
Zolla-Pazner, Susan .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2009, 25 (04) :441-450
[9]   The V3 domain of the HIV-1 gp120 envelope glycoprotein is critical for chemokine-mediated blockade of infection [J].
Cocchi, F ;
DeVico, AL ;
GarzinoDemo, A ;
Cara, A ;
Gallo, RC ;
Lusso, P .
NATURE MEDICINE, 1996, 2 (11) :1244-1247
[10]   NEUTRALIZATION OF PRIMARY HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 ISOLATES BY THE BROADLY REACTIVE ANTI-V3 MONOCLONAL-ANTIBODY, 447-52D [J].
CONLEY, AJ ;
GORNY, MK ;
KESSLER, JA ;
BOOTS, LJ ;
OSSORIOCASTRO, M ;
KOENIG, S ;
LINEBERGER, DW ;
EMINI, EA ;
WILLIAMS, C ;
ZOLLAPAZNER, S .
JOURNAL OF VIROLOGY, 1994, 68 (11) :6994-7000